AI Article Synopsis

  • This pilot study compares the effectiveness and safety of two treatments for neovascular glaucoma: diode laser transscleral cyclophotocoagulation (TSCP) and Ahmed glaucoma valve (AGV).
  • A total of 20 eyes from 19 subjects were analyzed over a follow-up period of more than 6 months, focusing on IOP control, visual outcomes, medication needs, and complications.
  • Results showed that both treatments effectively controlled IOP, but TSCP had fewer complications and required fewer follow-up procedures compared to AGV, although differences in visual outcomes were not statistically significant.

Article Abstract

Purpose: This is a pilot study to compare the effectiveness and safety of diode laser transscleral cyclophotocoagulation (TSCP) with the Ahmed glaucoma valve (AGV) in the management of neovascular glaucoma (NVG).

Methods: Eyes with NVG and an IOP greater than 21 mmHg on maximal medications, without previous glaucoma surgery or cyclodestruction, were randomized for either TSCP or AGV implantation. These eyes were followed for at least 6 months and analyzed with respect to their visual outcome, IOP, number of glaucoma medications required, and related complications.

Results: Twenty eyes (eight TSCP and 12 AGV) of 19 subjects with a follow-up duration of greater than 6 months were recruited. Mean follow-up duration was 28.5±17.9 and 31.0±15.4 months for the TSCP and AGV groups, respectively (=0.80). IOP was successfully controlled in 86% of the eyes for both interventions. By including preservation or improvement of visual acuity as additional criteria for overall success, success decreased to 63% for TSCP and 42% for AGV, although the difference was not statistically significant (=0.65). Eyes that had TSCP had fewer complications and required less subsequent procedures, compared to those that underwent AGV implantation.

Conclusion: Both procedures were equally effective in controlling the IOP and reducing glaucoma medications in NVG. However, eyes with AGV implant tended to have higher rates of visual loss and complications, as well as requiring more postoperative procedures, than eyes that were treated with TSCP, although the difference was not statistically significant.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292240PMC
http://dx.doi.org/10.2147/OPTH.S188999DOI Listing

Publication Analysis

Top Keywords

tscp agv
12
diode laser
8
laser transscleral
8
transscleral cyclophotocoagulation
8
ahmed glaucoma
8
glaucoma valve
8
neovascular glaucoma
8
pilot study
8
glaucoma medications
8
eyes tscp
8

Similar Publications

Purpose: This is a pilot study to compare the effectiveness and safety of diode laser transscleral cyclophotocoagulation (TSCP) with the Ahmed glaucoma valve (AGV) in the management of neovascular glaucoma (NVG).

Methods: Eyes with NVG and an IOP greater than 21 mmHg on maximal medications, without previous glaucoma surgery or cyclodestruction, were randomized for either TSCP or AGV implantation. These eyes were followed for at least 6 months and analyzed with respect to their visual outcome, IOP, number of glaucoma medications required, and related complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!